Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

• Gary Bloomgren, Sandra Richman, +8 authors Carmen Bozic
• The New England journal of medicine
• 2012

BACKGROUND Progressive multifocal leukoencephalopathy (PML) is associated with natalizumab treatment. We quantified the risk of PML in patients with multiple sclerosis, according to the presence or… (More)

Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

• Tatiana Plavina, M. Madhusudana Subramanyam, +7 authors Barry S Ticho
• Annals of neurology
• 2014

OBJECTIVE The increased risk of progressive multifocal leukoencephalopathy (PML) with natalizumab treatment is associated with the presence of anti-JC virus (JCV) antibodies. We analyzed whether… (More)

Risk factors for fungemia in children infected with human immunodeficiency virus: a case-control study.

• Corina E Gonzalez, David J Venzon, Sophia N C Lee, Brigitta U. Müller, Philip A. Pizzo, Thomas J Walsh
• Clinical infectious diseases : an official…
• 1996

To define the risk factors related to the occurrence of fungemia in children infected with human immunodeficiency virus (HIV), we performed a matched case-control study. During a 6-year period… (More)

CHD5 Downregulation Associated with Poor Prognosis in Epithelial Ovarian Cancer.

• Raymond R Y Wong, Loucia Kit-Ying Chan, +9 authors Tony Kwok Hung Chung
• Gynecologic and obstetric investigation
• 2011

BACKGROUND The CHD5 gene located on 1p36 encodes a protein-chromodomain helicase DNA-binding protein 5. CHD5 has been shown to be a tumor suppressor gene candidate. This study investigated the… (More)

Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.

• PaulA. Krogstad, Sophia N C Lee, +10 authors Andrew A. Wiznia
• Clinical infectious diseases : an official…
• 2002

The relative potency and tolerability of multidrug regimens used to treat infants and children infected with human immunodeficiency virus type 1 (HIV-1) are largely unknown. In Pediatric AIDS… (More)

Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis

• Diego Cadavid, Stephanie A Jurgensen, Sophia N C Lee
• PloS one
• 2013

BACKGROUND There is an unmet need for disease-modifying therapies to improve ambulatory function in disabled subjects with multiple sclerosis. OBJECTIVES Assess the effects of natalizumab on… (More)

Short-term effects of overnight orthokeratology on corneal epithelial permeability and biomechanical properties.

• Thao N. Yeh, Harry M Green, +5 authors Meng C Lin
• Investigative ophthalmology & visual science
• 2013

PURPOSE To investigate the effects of 30 nights of overnight orthokeratology (OOK) on corneal epithelial permeability (Pdc) and corneal biomechanical properties. METHODS BE Retainer and Paragon CRT… (More)

The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.

• Diego Cadavid, Jeffrey A. Cohen, +11 authors Daniel D. Mikol
• Multiple sclerosis
• 2017

BACKGROUND The Expanded Disability Status Scale (EDSS) has wide scientific and regulatory precedent but limited ability to detect clinically relevant disability progression in secondary progressive… (More)

An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.

• Bernard S. Goffe, K. R. Papp, +6 authors Barry S Ticho
• Clinical therapeutics
• 2005

BACKGROUND Information on longer-term safety and tolerability is needed to confidently prescribe alefacept therapy for chronic plaque psoriasis beyond 1 or 2 courses. OBJECTIVE The aim of this work… (More)

• ‹
• 1
• ›